Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
The month ahead: April’s upcoming events
AACR approaches, along with ASCO abstract titles.
Novartis gets a PSMAfore green flag at last
Pre-chemo prostate cancer beckons, but Pluvicto has a long way to go to hit $5bn sales.
ELCC 2025 – subQ Keytruda heads towards approval
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Make or break time for Caribou
The company’s matching strategy for CB-010 will soon be put to the test.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Imfinzi puts its flag on the Matterhorn
A hit on EFS will challenge regulators, and points to Merck's design blunder in Keynote-585.
